Carol Thomas Daily
Sharp analysis, broader horizons—your daily guide to the forces shaping our world.
About This Column
In Carol Thomas Daily, the analytical rigor previously reserved for the wellness tech sector is now applied to a wider spectrum of modern life and industry. Expanding her aperture, Carol explores the intersections of technology, business, culture, and lifestyle, dissecting the trends that shape how we live and work today.
Moving beyond niche vertical analysis, this column offers a daily synthesis of the forces driving change across various sectors. Whether unpacking complex market shifts, exploring societal trends, or offering critical perspectives on breaking news, Carol provides the context and clarity essential for navigating a rapidly evolving world. Carol Thomas Daily is the essential briefing for readers seeking to connect the dots between disparately emerging trends.
Displaying items 381-400 of 436 in total
Daingt Bets on Data to Lead the Global Korean Seaweed Boom
Tulsa Welding School Opens Atlanta Campus to Fill Skills Gap
MEXC's New Spot DCA Tool Aims to Tame Crypto Market Volatility
Lonza and Sidewinder Bet on Bispecific ADCs for Solid Tumors
i10X Raises $1M to Build the ‘Everything App’ for a Chaotic AI World
Medispend, RLDatix Merger Creates Life Sciences Compliance Powerhouse
Tempus AI: Charting AI's Future in Medicine at J.P. Morgan
CONTROLTEK Unifies Retail Tech with SmartPost Z™ Storefront Sensor
Your Smartphone is Now Your Car Key: The Global Standard Takes Hold
MSC Fund’s Smart Exit: A Mail Merger and a 33% Annual Return
Mazda's 2025 US Sales Dip Amid a Pivot to Premium and Safety
Patria Cements LatAm Lead with $3.5B Solis Credit Acquisition
A New Dimension: INCERGO Bets Big on Glasses-Free 3D at CES 2026
TomTom AI Maps: Paving the Road for Scalable Self-Driving Cars
Dr. Soon-Shiong's Oncology Honor Spotlights ImmunityBio's Ascent
Verizon's Q4 Earnings: A Test of Growth Amid Shifting Telecom Tides
Europi & Incus Forge Alliance for Iberian Logistics Dominance
ImmuCell Pivots to First Defense® After FDA Halts Re-Tain® Drug
AI's Double-Edged Sword: The $10 Trillion Cybersecurity Question
